Who was Barbara Mitchell?
  1. intellectual property for pharmaceuticals
  2. intellectual property for pharmaceuticals

intellectual property for pharmaceuticals

Janvier 30, 2017 4:46PM

Canada’s inadequate intellectual property rights protections hurt patients and the economy
Kristina M.L. Acri, née Lybecker
Printer-friendly version
There are numerous deficiencies that weaken intellectual property protections within Canada relative to other industrialized countries.
Étiquettes:
intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture
Janvier 24, 2017 1:00AM

Intellectual Property Rights Protection and the Biopharmaceutical Industry: How Canada Measures Up
Kristina M.L. Acri, née Lybecker
Printer-friendly version
Intellectual Property Rights Protection and the Biopharmaceutical Industry: How Canada Measures Up
Étiquettes:
intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture
Octobre 14, 2016 1:30AM

Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals
Steven Globerman, Kristina M.L. Acri, née Lybecker, Christopher Sands, Tomas J. Philipson
Printer-friendly version
Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals
Étiquettes:
intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture
Juillet 22, 2013 2:00AM

Stronger intellectual property for pharmaceuticals would benefit Canadians
Nadeem Esmail
Printer-friendly version

Canada's lagging intellectual property (IP) protections for pharmaceutical innovators are a key issue to be settled in the Comprehensive Economic and Trade Agreement (CETA) negotiations with the European Union. They may also play a role in upcoming negotiations for the multi-country Trans-Pacific Partnership (TPP). Two new essays on the cost and benefits of stronger protection suggest Canadians would be far better off, in both economic and health terms, with an IP protection regime for pharmaceutical innovators that was more closely aligned with international standards.

Étiquettes:
intellectual property rights, pharmaceutical industry, intellectual property for pharmaceuticals, new medicine, new drugs, property rights, trade, CETA, TPP, trans-pacific partnership